Baxalta (BXLT) Getting Somewhat Positive Media Coverage, Accern Reports
News coverage about Baxalta (NYSE:BXLT) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Baxalta earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 43.5962288489096 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Baxalta (BXLT) opened at $46.02 on Friday. Baxalta has a 12 month low of $29.83 and a 12 month high of $46.52.
WARNING: “Baxalta (BXLT) Getting Somewhat Positive Media Coverage, Accern Reports” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/baxalta-bxlt-getting-somewhat-positive-media-coverage-accern-reports/1694981.html.
Baxalta Company Profile
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR.
Receive News & Ratings for Baxalta Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.